Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Company working on COVID vaccine INO 4800
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
Subscribe To Our Newsletter & Stay Updated
